Racepinephrine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Racepinephrine
Accession Number
DB11124
Type
Small Molecule
Groups
Approved
Description

Racepinephrine is a racemic mixture consisting of d-epinephrine and l-epinephrine enantiomers which act as agonists at β adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingredient in oral inhalation products as racepinephrine hydrochloride.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Racepinephrine hydrochloride336096P2WE329-63-5ATADHKWKHYVBTJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
S2Solution2.25 %Respiratory (inhalation)Nephron Pharmaceuticals Corporation1998-10-02Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AsthmanefrinSolution11.25 mg/.5mLRespiratory (inhalation)Nephron Sc, Inc.2012-08-01Not applicableUs
Epi-MistAerosol, spray.594 mg/.12mLRespiratory (inhalation)Drnaturalhealing Inc2015-05-15Not applicableUs
S2Solution11.25 mg/.5mLRespiratory (inhalation)Cardinal Health2000-01-01Not applicableUs
S2Solution11.25 mg/.5mLRespiratory (inhalation)Nephron Sc, Inc.2000-01-01Not applicableUs
Categories
UNII
GR0L9S3J0F
CAS number
329-65-7
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Racepinephrine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Racepinephrine.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Racepinephrine.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Racepinephrine.Approved, Illicit, Investigational
AtomoxetineAtomoxetine may increase the hypertensive activities of Racepinephrine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Racepinephrine.Approved, Illicit
Benzylpenicilloyl PolylysineRacepinephrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Bucindolol.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Racepinephrine.Investigational
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Racepinephrine.Approved, Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Racepinephrine.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Racepinephrine.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Racepinephrine.Illicit, Withdrawn
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Racepinephrine.Approved, Investigational, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Racepinephrine.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved, Investigational
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Racepinephrine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Racepinephrine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Racepinephrine.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Racepinephrine.Approved
EpanololThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Racepinephrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Racepinephrine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Racepinephrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Racepinephrine.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Fenozolone.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Racepinephrine.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Racepinephrine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Racepinephrine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Racepinephrine.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Racepinephrine.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Racepinephrine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Racepinephrine.Approved
LacidipineRacepinephrine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Racepinephrine.Approved, Investigational
LinezolidLinezolid may increase the hypertensive activities of Racepinephrine.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Racepinephrine can be increased when used in combination with Lorpiprazole.Approved
MefenorexThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Racepinephrine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Racepinephrine.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Racepinephrine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Racepinephrine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Racepinephrine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Racepinephrine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Racepinephrine.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Racepinephrine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Racepinephrine.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Racepinephrine.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Racepinephrine.Approved, Investigational
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Racepinephrine.Approved, Illicit
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Racepinephrine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Racepinephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Racepinephrine.Approved, Vet Approved, Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Racepinephrine.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Pseudoephedrine.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Racepinephrine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Racepinephrine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Racepinephrine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Racepinephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Racepinephrine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Racepinephrine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Racepinephrine.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Racepinephrine.Approved
TramazolineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Tramazoline.Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Tretoquinol.Experimental
TrimazosinTrimazosin may decrease the vasoconstricting activities of Racepinephrine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Racepinephrine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Racepinephrine.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Racepinephrine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911128
Wikipedia
Racepinephrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableNot Yet RecruitingPreventionDysphonia / Postoperative pain / Swallowing Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Aerosol, sprayRespiratory (inhalation).594 mg/.12mL
SolutionRespiratory (inhalation)11.25 mg/.5mL
SolutionRespiratory (inhalation)2.25 %
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on December 03, 2015 09:51 / Updated on February 03, 2018 14:01